MiniVax Adds Dr. Bruce Beutler, 2011 Nobel Laureate in Medicine, as Scientific Advisor

NEW ORLEANS--()--Today, MiniVax, Inc. (MiniVax), a company specializing in the development of treatments for opportunistic fungal and bacterial infections, announced Dr. Bruce Beutler as the most recent addition to its Scientific Advisory Board. Dr. Beutler has over 25 years of experience in immunology research and is currently Director of the Center for the Genetics of Host Defense at the University of Texas Southwestern Medical Center. Dr. Beutler has made numerous significant achievements in the study of immunology and was recently a co-recipient of the 2011 Nobel Prize in Medicine for the discovery of the key mammalian sensors of microbial infections. Dr. Beutler’s expertise in the field of immunology will be of considerable value for MiniVax as it plans the next steps of product development for its vaccine and monoclonal antibody therapeutic against Pneumocystis pneumonia (PCP), the most common opportunistic infection in HIV/AIDS patients.

Pneumocystis pneumonia and other fungal and bacterial infections affect countless individuals, but there are still relatively few treatment options and in many cases these options are ineffective. MiniVax has a platform technology that could provide solutions to numerous indications and save many lives. I am excited to be engaged directly with MiniVax and look forward to working with the team throughout the product development process,” said Dr. Beutler.

“MiniVax is excited and humbled to have someone of Dr. Beutler’s caliber on the Scientific Advisory Board,” said Dr. A. Ray Chaudhuri, MiniVax’s CEO. “He brings a wealth of knowledge and experience to MiniVax that will be invaluable as we proceed further down the commercialization path.”

About MiniVax

MiniVax, Inc. (MiniVax) is a New Orleans, LA based company that specializes in the research and development of novel vaccines and therapeutics for the treatment and prevention of opportunistic fungal and bacterial infections. MiniVax’s lead product is a vaccine against the opportunistic fungal infection Pneumocystis pneumonia (PCP), which predominately affects immunocompromised individuals. MiniVax anticipates beginning in-human FDA clinical trials for the vaccine in 2013. A secondary focus of MiniVax is the development of a monoclonal antibody therapeutic for the treatment of those individuals who are already suffering from a Pneumocystis infection. MiniVax occupies office and laboratory space at the New Orleans BioInnovation Center (NOBIC).

For more information:
504-264-2829
info@minivaxcorp.com
www.minivaxcorp.com

Contacts

MiniVax, Inc.
William Heim, 504-264-3320
wheim@minivaxcorp.com

Contacts

MiniVax, Inc.
William Heim, 504-264-3320
wheim@minivaxcorp.com